Hera BioLabs, Inc.
Hera is a pioneer in Precision Toxicology™ - Generating high-confidence, clinically-relevant toxicology profiles with greater predictability.
- Stage $500K in TTM Revenue
- Industry Biotechnology
- Location Lexington, KY, US
- Currency USD
- Founded January 2015
- Employees 10
- Incorporation Type C-corp
- Website herabiolabs.com
A major reason for drug development failures is that human specific toxicity is missed in traditionally used pre-clinical cell lines (in vitro testing) and animal models (in vivo testing). Hera has the unique ability to create more predictive animal and cellular models, and is pursuing a two pronged, in vivo and in vitro, strategy.
M.Sc. Biotechnology - University of Pennsylvania - Built revenue at Transposagen the sister company of Hera from $0 to $18MM over a 4 year period, in & out-licensing, IP & technology evaluation, go to market execution, management of scientists and business personnel, grant management and accounting experience
scientific program management & execution, gene editing and cell culture expert
Chris Chengelis Ph.D.Senior Scientific Adviser
30 years+ experience in the preclinical toxicology industry, facility design, study design and execution, industry & regulatory connections
Eric OstertagFounder & Director
founder of multiple biotech companies including Transposagen and Poseida Therapeutics, valuation >$100MM
Starting a startup?
Join the world's largest startup network for guidance, tools, and fundraising opportunities.